NEW YORK – Kazia Therapeutics and Kintara Therapeutics said on Thursday that studies involving their drugs will begin enrolling patients within the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) platform trial.
Within GBM AGILE, an international adaptive study sponsored by the Global Coalition for Adaptive Research (GCAR), collaborators aim to find new treatments for glioblastoma. The study's design allows for multiple therapies from different pharma companies to be evaluated simultaneously.